Pharma &amp; Biotech

Biotechnology firm Xilio Development is set to present new preclinical findings for its drug candidate XTX601 at the upcoming American...

Arvinas Shares a Key Development in Parkinson’s Disease Treatment

by Kennethcix

New clinical data presented this week by Arvinas at a specialist conference in Copenhagen has marked a significant advance for...

Shareholders Await Payout as Vyant Bio Liquidation Drags On

The dissolution of biotechnology firm Vyant Bio continues to proceed at a slower pace than initially outlined. While shareholders approved...

Analyst Sentiment Shifts as Ocugen Gains Second Major Backer

The investment thesis for biopharmaceutical company Ocugen is gaining notable support on Wall Street. In a significant endorsement, the firm...

Healwell AI’s Pivotal Year: A Milestone Assessment

Today marks a significant confluence of events for Healwell AI Inc. The company is releasing its complete fiscal 2025 annual...

Valneva’s Strategic Pivot: Sharply Reduced Cash Burn Signals Operational Progress

French vaccine specialist Valneva has unveiled its full-year 2025 results, presenting a nuanced financial picture that underscores a significant improvement...

Ocugen’s High-Stakes Path Forward: Balancing Breakthrough Potential with Financial Strain

The biotech firm Ocugen has staged a remarkable recovery in recent months, capturing renewed attention from institutional investors. This resurgence...

HSBC Issues Rare Sell Rating on High-Flying Pharma Giant Eli Lilly

In a move that sent shockwaves through the market, global banking giant HSBC has downgraded its stance on Eli Lilly...

Hims & Hers Expands Weight Loss Portfolio with Novo Nordisk Partnership

The telehealth company Hims & Hers has taken a decisive step into the competitive GLP-1 market. It has now opened...

CytomX Secures Major Funding to Advance Key Cancer Drug Candidate